BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38588933)

  • 1. Breast cancer drug resistance: Decoding the roles of Hippo pathway crosstalk.
    Dehghanian F; Ghahnavieh LE; Nilchi AN; Khalilian S; Joonbakhsh R
    Gene; 2024 Jul; 916():148424. PubMed ID: 38588933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer.
    Mohajan S; Jaiswal PK; Vatanmakarian M; Yousefi H; Sankaralingam S; Alahari SK; Koul S; Koul HK
    Cancer Lett; 2021 Jun; 507():112-123. PubMed ID: 33737002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?
    Margariti N; Fox SB; Bottini A; Generali D
    Breast Cancer Res Treat; 2011 Aug; 128(3):599-606. PubMed ID: 20945086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippo pathway in mammary gland development and breast cancer.
    Shi P; Feng J; Chen C
    Acta Biochim Biophys Sin (Shanghai); 2015 Jan; 47(1):53-9. PubMed ID: 25467757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
    Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
    EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing therapeutic resistance in breast cancer: from the lncRNAs perspective.
    Peng L; Jiang J; Tang B; Nice EC; Zhang YY; Xie N
    Theranostics; 2020; 10(23):10360-10377. PubMed ID: 32929354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling.
    He Z; Zhao TT; Jin F; Li JG; Xu YY; Dong HT; Liu Q; Xing P; Zhu GL; Xu H; Miao ZF
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2340-2347. PubMed ID: 29964010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
    Zhang Z; Qiu N; Yin J; Zhang J; Liu H; Guo W; Liu M; Liu T; Chen D; Luo K; Li H; He Z; Liu J; Zheng G
    Theranostics; 2020; 10(10):4290-4307. PubMed ID: 32292495
    [No Abstract]   [Full Text] [Related]  

  • 10. Emerging roles of exosomal miRNAs in breast cancer drug resistance.
    Najminejad H; Kalantar SM; Abdollahpour-Alitappeh M; Karimi MH; Seifalian AM; Gholipourmalekabadi M; Sheikhha MH
    IUBMB Life; 2019 Nov; 71(11):1672-1684. PubMed ID: 31322822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hippo signaling pathway: A comprehensive gene expression profile analysis in breast cancer.
    Yousefi H; Delavar MR; Piroozian F; Baghi M; Nguyen K; Cheng T; Vittori C; Worthylake D; Alahari SK
    Biomed Pharmacother; 2022 Jul; 151():113144. PubMed ID: 35623167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis.
    Chen W; Zhou S; Mao L; Zhang H; Sun D; Zhang J; Li J; Tang JH
    Tumour Biol; 2016 Aug; 37(8):10011-9. PubMed ID: 27153853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Hippo pathway as a drug target in gastric cancer.
    Qiao Y; Li T; Zheng S; Wang H
    Cancer Lett; 2018 Apr; 420():14-25. PubMed ID: 29408652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hippo pathway in chemotherapeutic drug resistance.
    Zhao Y; Yang X
    Int J Cancer; 2015 Dec; 137(12):2767-73. PubMed ID: 25348697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
    BeLow M; Osipo C
    Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug target strategies in breast cancer treatment: recent developments.
    Mayank ; Jaitak V
    Anticancer Agents Med Chem; 2014; 14(10):1414-27. PubMed ID: 24712325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INHBA regulates Hippo signaling to confer 5-FU chemoresistance mediated by cellular senescence in colon cancer cells.
    Zhang Z; Chen L; Yang Q; Tang X; Li J; Zhang G; Wang Y; Huang H
    Int J Biochem Cell Biol; 2024 Jun; 171():106570. PubMed ID: 38588888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance.
    Zhang Y
    Pharmacol Ther; 2021 Feb; 218():107677. PubMed ID: 32898548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitigation of Breast Cancer Cells' Invasiveness via Down Regulation of ETV7, Hippo, and PI3K/mTOR Pathways by Vitamin D3 Gold-Nanoparticles.
    Roy M; Hussain F
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.